Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Medtronic
Covington
US Army
Queensland Health
Novartis
Mallinckrodt
Accenture
Federal Trade Commission
Merck

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,197,819

« Back to Dashboard

Which drugs does patent 6,197,819 protect, and when does it expire?


Patent 6,197,819 protects LYRICA and LYRICA CR and is included in three NDAs. There have been two Paragraph IV challenges on Lyrica.

This patent has thirty-six patent family members in twenty-two countries.

Summary for Patent: 6,197,819

Title: Gamma amino butyric acid analogs and optical isomers
Abstract:A compound of the formula ##STR1## wherein R.sub.1 is a straight or branched alkyl group having from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R.sub.2 is hydrogen or methyl; and R.sub.3 is hydrogen, methyl or carboxyl; which is useful in the treatment of seizure disorders. Processes are disclosed for the preparation of the compound. Intermediates prepared during the synthesis of the compound are also disclosed.
Inventor(s): Silverman; Richard B. (Morton Grove, IL), Andruszkiewicz; Ryszard (Sopot, PL)
Assignee: Northwestern University (Evanston, IL)
Application Number:08/420,905
Patent Claim Types:
see list of patent claims
Compound; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Pf Prism CvLYRICApregabalinCAPSULE;ORAL021446-001Dec 30, 2004RXYesNo► Subscribe► Subscribe► SubscribeYY
Pf Prism CvLYRICApregabalinCAPSULE;ORAL021446-002Dec 30, 2004RXYesNo► Subscribe► Subscribe► SubscribeYY
Pf Prism CvLYRICApregabalinCAPSULE;ORAL021446-003Dec 30, 2004RXYesNo► Subscribe► Subscribe► SubscribeYY
Pf Prism CvLYRICApregabalinCAPSULE;ORAL021446-004Dec 30, 2004RXYesNo► Subscribe► Subscribe► SubscribeYY
Pf Prism CvLYRICApregabalinCAPSULE;ORAL021446-005Dec 30, 2004RXYesNo► Subscribe► Subscribe► SubscribeYY
Pf Prism CvLYRICApregabalinCAPSULE;ORAL021446-006Dec 30, 2004RXYesNo► Subscribe► Subscribe► SubscribeYY
Pf Prism CvLYRICApregabalinCAPSULE;ORAL021446-007Dec 30, 2004RXYesNo► Subscribe► Subscribe► SubscribeYY
Pf Prism CvLYRICApregabalinCAPSULE;ORAL021446-008Dec 30, 2004RXYesYes► Subscribe► Subscribe► SubscribeYY
Pf Prism CvLYRICApregabalinSOLUTION;ORAL022488-001Jan 4, 2010RXYesYes► Subscribe► Subscribe► SubscribeYY
Pfizer IncLYRICA CRpregabalinTABLET, EXTENDED RELEASE;ORAL209501-001Oct 11, 2017RXYesNo► Subscribe► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,197,819

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,028,214 GABA and L-glutamic acid analogs for antiseizure treatment► Subscribe
6,414,024 GABA and L-glutamic acid analogs for antiseizure treatment► Subscribe
6,291,526 GABA and L-glutamic acid analogs for antiseizure treatment► Subscribe
5,563,175 GABA and L-glutamic acid analogs for antiseizure treatment► Subscribe
6,117,906 GABA and L-glutamic acid analogs for antiseizure treatment► Subscribe
6,342,529 GABA and L-glutamic acid analogs for antiseizure treatment► Subscribe
6,140,366 GABA and L-glutamic acid analogs for antiseizure treatment► Subscribe
5,847,151 Gaba and L-glutamic acid analogs for antiseizure treatment► Subscribe
5,684,189 GABA and L-glutamic acid analogs for antiseizure treatment► Subscribe
6,255,345 GABA and L-glutamic acid analogs for antiseizure treatment► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,197,819

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria207052► Subscribe
Australia4379493► Subscribe
Australia677008► Subscribe
Australia9137091► Subscribe
Canada2134674► Subscribe
Czech Republic286106► Subscribe
Czech Republic9402849► Subscribe
Germany122004000039► Subscribe
Germany69330949► Subscribe
Denmark0641330► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Federal Trade Commission
Citi
Teva
Accenture
QuintilesIMS
Covington
Queensland Health
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot